Olmesta 10 mg Tablet should be taken orally, once daily, with or without food. It is recommended to take the tablet at approximately the same time each day to maintain consistent blood pressure control.

Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, in the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced peripheral resistance, and subsequently, a decrease in blood pressure.

• •Hypersensitivity to olmesartan medoxomil or any component of the product.
• •Pregnancy (especially during the second and third trimesters) due to risk of fetal harm.
• •Bilateral renal artery stenosis.
• •Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²).
• •Severe hepatic impairment or biliary obstruction.

Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia (fast heartbeat) or bradycardia (slow heartbeat). Management involves symptomatic and supportive treatment. If ingestion is recent, induce vomiting or perform gastric lavage. Intravenous fluids may be administered to counteract hypotension.

Pregnancy: Contraindicated during the second and third trimesters due to potential for fetal injury and death. If pregnancy is detected, discontinue Olmesartan as soon as possible. Lactation: It is not known whether olmesartan is excreted in human milk, but a risk to the nursing infant cannot be excluded. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.